Navigation Links
Dr. Michael Brownlee receives JDRF Rumbough Award for Scientific Excellence
Date:5/19/2008

May 19, 2008 (BRONX, NY) Michael Brownlee, M.D., the Anita and Jack Saltz Professor of Diabetes Research at Albert Einstein College of Medicine of Yeshiva University, has been selected by the Juvenile Diabetes Research Foundation (JDRF) to receive the prestigious David Rumbough Award for Scientific Excellence. The award recognizes researchers for their outstanding achievement and commitment to diabetes research. Actress Dina Merrill established this award in 1974 in honor of her late son, David.

Upon the presentation of the award, Ms. Merrill noted, I am honored to join with you tonight in the presentation of the David Rumbough Award for Scientific Excellence, which was established in honor of my late, beloved son, David. He would have been very pleased to know that research towards a cure is progressing rapidly and improving the lives of so many. Keep up the good work.

Dr. Brownlee is one of the most respected and influential scientists in his field and is noted for his innovative approach to understanding the biochemical basis of diabetic complications. He is internationally recognized for his research including his discovery of a novel molecular pathway linking hyperglycemia to diabetic retinopathy, a complication of the disease.

His propensity for creative exploration has also led to other notable contributions to the field of knowledge in understanding type 1 diabetes and its complications. For example, through his studies, Dr. Brownlee has established that the four seemingly independent biochemical pathways found to contribute to hyperglycemia-induced damage in type 1 diabetes polyol pathway activation, advanced glycation endproduct (AGE) formation, protein kinase C (PKC), and hexosamine pathway activation all arise from a single hyperglycemia-induced process that is initiated by overproduction of toxic free radicals produced by the cells mitochondria. He also has demonstrated that normalizing free-radical levels inhibits the pathways through which cell damage occurs. And, his research of benfotiamine, a synthetic derivative of the dietary supplement thiamine (vitamin B1), found that it blocked all major pathways of hyperglycemic damage, and that it blocked formation of structural lesions in the retinas of long-term diabetic animals. His current studies include clinical trials of benfotiamine.

Dr. Brownlee also is the Director of the JDRF International Center for Diabetic Complications Research at Einstein. All of the projects in this Center share an overriding aim: to develop innovative, highly effective therapies for preventing the development and progression of retinopathy, nephropathy, neuropathy, and atherosclerosis in type 1 patients.

In 2006, JDRF awarded Dr. Brownlee with its Scholar Award. His contributions to the field have also been extensively recognized through his receipt of other prestigious awards, including the 2005 Naomi Berrie Award for Outstanding Achievement in Diabetes Research from Columbia University Medical Center; the 2004 Banting Medal, the highest scientific award of the American Diabetes Association; the 2004 Davis Award from the Childrens Diabetes Foundation; the 2003 Claude Bernard Medal, the highest scientific honor given by the European Association for the Study of Diabetes; and the 1993 Outstanding Scientific Achievement Award, presented by the American Diabetes Association.

In addition to Dr. Brownlee, a 2008 JDRF Rumbough Award also was presented to Dr. Michael German, of the University of California San Francisco.


'/>"/>

Contact: Karen Gardner
kgardner@aecom.yu.edu
718-430-3101
Albert Einstein College of Medicine
Source:Eurekalert

Related medicine news :

1. Michael A. Sandler, MD, Installed as President of Michigan State Medical Society
2. Mylan Appoints Michael J. Monroe Senior Vice President for Global Public Affairs
3. Michael E. DeBakey Receives Congressional Gold Medal
4. Consumers Research Council of America Names Pediatrician Michael Y. Wu, MD, MBA as One of Americas Top Pediatricians
5. Childhood Obesity Expert Dr. William Dietz Featured at the 2nd Annual Michael & Susan Dell Lectureship in Child Health
6. Michael D. Farley Appointed Chief Operating Officer of Lupus Foundation of America, Inc.
7. Michael J. Fox Foundation Commits Up to $2 Million to Improve Drug Delivery for Parkinsons Disease
8. Michael A. Giaquinto to Join Greenhill as a Managing Director
9. STERIS Corporation Names Michael J. Tokich Chief Financial Officer
10. Cardinal Health Names Michael C. Kaufmann to Lead Pharmaceutical Segment
11. Cultivating the Smart Patient: Author and RealAge Founder Michael F. Roizen, MD to Present Keynote at URAC Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... , ... April 29, 2016 , ... In an ... and divorcee, shares her enthusiasm for Botox and lip injections, which she underwent in ... youth oriented Coachella Valley Music and Arts Festival. The article explains that Ms. Mirmelli’s ...
(Date:4/29/2016)... ... April 29, 2016 , ... Shamangelic Healing, ... addition Onnit brand Alpha BRAIN and New Mood Daily-Stress Formula for brain optimization ... optimization products to the store is just one more way Shamangelic Healing supports ...
(Date:4/29/2016)... ... April 29, 2016 , ... The American workforce is ... even security. Most importantly, employees are the single most important asset in creating ... so unhappy? , Just under half of American workers are emotionally checked out ...
(Date:4/29/2016)... ... 2016 , ... Conditions were ideal for Global Lyme Alliance’s (GLA) 2nd annual ... skies, a light breeze and temperatures in the 60s. Over 400 runners, walkers and ... Walk and 1-mile walk were held to increase awareness about Lyme disease and ...
(Date:4/29/2016)... ... 2016 , ... Spine Team Texas, a comprehensive spine physician group specializing in ... physicians has been invited to be a featured speaker at the Texas Society of ... April 30, 2016. , Dr. R. Scott McPherson, a physical medicine and rehabilitation ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)...  Hologic, Inc. (Nasdaq: HOLX ) ... fiscal second quarter ended March 26, 2016.  GAAP ... 41.2%, and non-GAAP diluted EPS of $0.47 increased ... a reported basis, and 6.3% on a constant ... good quarter, highlighted by 14.6% growth in non-GAAP ...
(Date:4/27/2016)... ALBANY, New York , April 27, 2016 /PRNewswire/ ... new market report titled, "Skincare Devices Market - Global ... - 2023." According to the report, the global skincare ... 2014 and is anticipated to expand at a CAGR ... 17,299.4 Mn in 2023. Browse the full Skincare ...
(Date:4/27/2016)... 2016 Research and ... Anesthesia Disposables Market 2016-2020"  report to their ... ,The global anesthesia disposables market is set ... during the period 2016-2020.  Healthcare-acquired ... patients, safety. Organizations like the CDC and ...
Breaking Medicine Technology: